J Extra Corpor Technol
Volume 39, Number 4, December 2007
|Page(s)||296 - 301|
|Published online||15 December 2007|
Pharmacologic Neuroprotection: The Search Continues
Author for correspondence: Hilary P. Grocott, email@example.com
Dozens of drugs have been studied in an attempt to mitigate the adverse cerebral consequences of cardiac surgery. The targets for these drugs have focused on pathways identified through the cascade of events that occurs once cerebral ischemia is initiated. In addition, inflammatory targets specific to cardio-pulmonary bypass have also been addressed. Although no drugs are yet approved as specific neuroprotective agents, trials continue of increasingly unique targets, with fewer unwanted side effects and acting through novel mechanisms of action. This review summarizes the past, present, and future of pharmacologic neuroprotection for cardiac surgery.
Key words: cardiac surgery / cardiopulmonary bypass / brain / neuroprotection / pharmacology
© 2007 AMSECT
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.